

## PRESS RELEASE

30 June 2011



### **New number of shares and votes in BioInvent International AB (publ)**

BioInvent International AB (publ) (OMXS: BINV) today announced that the company's total number of shares as per 30 June 2011 amounts to 67,205,257 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from an issue of 6,109,568 shares under BioInvent's directed new share issue that was announced on 1 June 2011.

-- END --

#### **Notes to Editors:**

##### **About BioInvent**

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

The company's competitive position is underpinned by an in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, UCB and XOMA. More information is available at [www.bioinvent.com](http://www.bioinvent.com).

#### **For further information, please contact:**

##### ***BioInvent International AB***

Svein Mathisen  
President & CEO  
Tel: +46 (0)46-286 85 67  
Mobile: +46 (0)708-97 82 13  
E-mail: [svein.mathisen@bioinvent.com](mailto:svein.mathisen@bioinvent.com)

Sten Westerberg  
Vice President, Investor Relations  
Tel: +46 (0)46-286 85 52  
Mobile: +46 (0)768-68 50 09  
E-mail: [sten.westerberg@bioinvent.com](mailto:sten.westerberg@bioinvent.com)

##### **BioInvent International AB (publ)**

Co. reg. No. 556537-7263,  
Address: Sölvegatan 41  
Mailing address: SE-223 70 LUND  
Tel: +46 (0)46 286 85 50  
[info@bioinvent.com](mailto:info@bioinvent.com)  
[www.bioinvent.com](http://www.bioinvent.com)

*Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. CET, on 30 June, 2011.*